吉非替尼治疗晚期非小细胞肺癌临床研究

目的观察吉非替尼治疗晚期非小细胞肺癌的疗效及毒副反应。方法30例经放、化疗治疗失败的非小细胞肺癌患者,其中5例肿瘤局限于胸腔内,25例已有远处转移。吉非替尼剂量为250 mg/d,口服,每天1次,全组用药的中位时间为4个月。结果30例患者中,完全缓解1例,部分缓解8例,稳定10例,进展11例。全组有效率30.0%,疾病控制率为63.3%,中位生存期5.3个月（1～18个月）,1年生存率为43.3%。主要毒副作用是皮疹,共发生11例,占36.7%;其他毒副作用为腹泻,转氨酶升高。结论吉非替尼对放、化疗失败的晚期非小细胞肺癌有较好的治疗效果,且毒副反应轻。

Gefitinib in the treatment of patients with advanced non-small cell lung cancer

Objective To evaluate the efficacy and toxicity of gefitinib in treatment of patients with advanced non-small cell lung cancer （NSCLC）. Methods Thirty patients with NSCLC who failed in prior chemotherapy and radiotherapy were studied. Prior to gefitinib therapy, 25 patients were in stage IV and 5 patients in stage Ⅲ B. Gefitinib was administered orally at 250mg, once a day until cancer progressed or severe toxicity occurred. The median time for administration of gefitinih was 4 months. Results Of the 30 patients, 1 got complete response （CR） , 8 partial response（PR） , 10 stable disease（SD） , and 11 progress of disease （PD）. The total response rate was 30.0% and disease control rate including response and stable disease was 63.3%. The median survival time was 5.3 months. The 1 year survival rate was 43.3%. The main toxicity of gefitinib was skin toxicity （rash） and 11 cases had rash （36. 7% of the whole group）. Other toxicreactions were diarrhea and elevation of transaminase. Conclusion Gefitinib is effective and tolerable for the patients with NSCLC who failed in prior chemotherapy and radiotherapy.